Compare Glenmark Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs LUPIN - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA LUPIN GLENMARK PHARMA/
LUPIN
 
P/E (TTM) x 14.6 41.4 35.2% View Chart
P/BV x 2.4 3.8 63.0% View Chart
Dividend Yield % 0.4 0.6 73.8%  

Financials

 GLENMARK PHARMA   LUPIN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
LUPIN
Mar-20
GLENMARK PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs712882 80.7%   
Low Rs484505 95.8%   
Sales per share (Unadj.) Rs349.6339.4 103.0%  
Earnings per share (Unadj.) Rs32.8-5.9 -551.2%  
Cash flow per share (Unadj.) Rs44.315.5 286.5%  
Dividends per share (Unadj.) Rs2.006.00 33.3%  
Dividend yield (eoy) %0.30.9 38.7%  
Book value per share (Unadj.) Rs198.6276.7 71.8%  
Shares outstanding (eoy) m282.17453.00 62.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.72.0 83.6%   
Avg P/E ratio x18.2-116.6 -15.6%  
P/CF ratio (eoy) x13.544.8 30.1%  
Price / Book Value ratio x3.02.5 120.0%  
Dividend payout %6.1-100.9 -6.0%   
Avg Mkt Cap Rs m168,625314,201 53.7%   
No. of employees `00012.018.3 65.8%   
Total wages/salary Rs m20,56129,868 68.8%   
Avg. sales/employee Rs Th8,196.08,400.6 97.6%   
Avg. wages/employee Rs Th1,708.11,632.0 104.7%   
Avg. net profit/employee Rs Th768.5-147.2 -522.1%   
INCOME DATA
Net Sales Rs m98,655153,748 64.2%  
Other income Rs m2,0814,838 43.0%   
Total revenues Rs m100,736158,585 63.5%   
Gross profit Rs m15,85824,849 63.8%  
Depreciation Rs m3,2599,702 33.6%   
Interest Rs m3,3463,630 92.2%   
Profit before tax Rs m11,33516,355 69.3%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m1,672-7,521 -22.2%   
Tax Rs m3,75611,571 32.5%   
Profit after tax Rs m9,250-2,694 -343.4%  
Gross profit margin %16.116.2 99.5%  
Effective tax rate %33.170.8 46.8%   
Net profit margin %9.4-1.8 -535.1%  
BALANCE SHEET DATA
Current assets Rs m66,968154,132 43.4%   
Current liabilities Rs m40,21192,252 43.6%   
Net working cap to sales %27.140.2 67.4%  
Current ratio x1.71.7 99.7%  
Inventory Days Days8382 101.5%  
Debtors Days Days81129 62.8%  
Net fixed assets Rs m33,32289,082 37.4%   
Share capital Rs m282906 31.1%   
"Free" reserves Rs m55,770124,461 44.8%   
Net worth Rs m56,052125,367 44.7%   
Long term debt Rs m35,73817,933 199.3%   
Total assets Rs m132,888249,839 53.2%  
Interest coverage x4.45.5 79.7%   
Debt to equity ratio x0.60.1 445.7%  
Sales to assets ratio x0.70.6 120.6%   
Return on assets %9.50.4 2,530.3%  
Return on equity %16.5-2.1 -768.0%  
Return on capital %17.88.7 204.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99851,450 122.4%   
Fx outflow Rs m22,85919,470 117.4%   
Net fx Rs m40,14031,980 125.5%   
CASH FLOW
From Operations Rs m13,24214,688 90.2%  
From Investments Rs m-6,99011,070 -63.1%  
From Financial Activity Rs m-7,387-8,906 83.0%  
Net Cashflow Rs m-2,97116,853 -17.6%  

Share Holding

Indian Promoters % 48.3 46.6 103.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 6.9 11.3 61.1%  
FIIs % 34.4 31.9 107.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   56,727 98,259 57.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT PHARMOVA   SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 447 Points Higher; Automobile & IT Stocks Rally(Closing)

Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 2, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS